Targeted trials in ovarian cancer

Gynecologic Oncology

Volumn 119, Issue 1, 2010, Pages 151-156

  Ledermann, Jonathan A ^a   Raja, Fharat A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Bevacizumab; Molecular targeted therapy; Ovarian cancer; PARP inhibitors

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; AFLIBERCEPT; AGO 14699; AMG 479; BEVACIZUMAB; BIBF 1120; BSI 201; CARBOPLATIN; CEDIRANIB; CETUXIMAB; DASATINIB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; MK 4827; MORAB 003; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; CANCER GROWTH; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISEASE MARKER; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; DRUG DELIVERY SYSTEM; OVARIAN NEOPLASMS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77956648238     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.05.008     Document Type: Review

References (51)

1. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
2. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
3. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 2008 579 591
4. B.H. Jeon, C. Jang, J. Han, R.P. Kataru, L. Piao, K. Jung, H.J. Cha, R.A. Schwendener, K.Y. Jang, K.S. Kim, K. Alitalo, and G.Y. Koh Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer Cancer Res 68 2008 1100 1109
5. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 2001 987 989
6. E.A. Boss, L.F. Massuger, C.M. Thomas, A. Geurts-Moespot, H. Boonstra, and C.G. Sweep Vascular endothelial growth factor in ovarian cyst fluid Cancer 91 2001 371 377
7. A. Kraft, K. Weindel, A. Ochs, C. Marth, J. Zmija, P. Schumacher, C. Unger, D. Marme, and G. Gastl Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease Cancer 85 1999 178 187
8. B.K. Zebrowski, W. Liu, K. Ramirez, Y. Akagi, G.B. Mills, and L.M. Ellis Markedly elevated levels of vascular endothelial growth factor in malignant ascites Ann Surg Oncol 6 1999 373 378
9. A.T. Byrne, L. Ross, J. Holash, M. Nakanishi, L. Hu, J.I. Hofmann, G.D. Yancopoulos, and R.B. Jaffe Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model Clin Cancer Res 9 2003 5721 5728
10. H. Chen, D. Ye, X. Xie, B. Chen, and W. Lu VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma Gynecol Oncol 94 2004 630 635
11. T.J. Duncan, A. Al-Attar, P. Rolland, I.V. Scott, S. Deen, D.T. Liu, I. Spendlove, and L.G. Durrant Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14 2008 3030 3035
12. P.J. Paley, K.A. Staskus, K. Gebhard, D. Mohanraj, L.B. Twiggs, L.F. Carson, and S. Ramakrishnan Vascular endothelial growth factor expression in early stage ovarian carcinoma Cancer 80 1997 98 106
13. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
14. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, H. Mackey, J. Douglas, R.A. Burger, D. Armstrong, R. Wenham, and W. McGuire Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186
15. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, L. Roman, S. Groshen, S. Swenson, F. Markland, D. Gandara, S. Scudder, R. Morgan, H. Chen, H.J. Lenz, and A.M. Oza Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
16. E.S. Han, and B.J. Monk What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105 2007 3 6
17. M.P. Smerdel, M. Waldstrøm, I. Brandslund, K.D. Steffensen, R.F. Andersen, and A. Jakobsen Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer Int J Gynecol Cancer 19 2009 578 584 [abstr]
18. J. Holash, S. Davis, N. Papadopoulos, S.D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, E. Ioffe, T. Huang, C. Radziejewski, K. Bailey, J.P. Fandl, T. Daly, S.J. Wiegand, G.D. Yancopoulos, and J.S. Rudge VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398
19. N. Colombo, G. Mangili, S. Mammoliti, M. Kalling, B. Tholander, L. Sternas, G. Buzenet, and D. Chamberlain Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study Proc Am Soc Clin Oncol 26 2008 1498 [abstr]
20. M.H. Friedlander, K.C. Benigno, B. Rischin, D. Messing, M. Stringer, C.A. Hodge, J.P. Ma, B. Matthys, G. Lager, and J.J. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: results of a phase 2 study Ann Oncol 19 2008 211 216 abstr 6630
21. U.A. Matulonis, S. Berlin, P. Ivy, K. Tyburski, C. Krasner, C. Zarwan, A. Berkenblit, S. Campos, N. Horowitz, S.A. Cannistra, H. Lee, J. Lee, M. Roche, M. Hill, C. Whalen, L. Sullivan, C. Tran, B.D. Humphreys, and R.T. Penson Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol 27 2009 5601 5606
22. J.A. Rauh-Hain, and R.T. Penson Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma Int J Gynecol Cancer 18 2008 934 936
23. J. Ledermann, G. Rustin, A. Hackshaw, and S.B. Kaye A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC) Proc Am Soc Clin Oncol 27 2009 5501 [abstr]
24. J.M. Lafky, J.A. Wilken, A.T. Baron, and N.J. Maihle Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer Biochim Biophys Acta 1785 2008 232 265
25. P. de Graeff, A.P. Crijns, S. de Jong, M. Boezen, W.J. Post, E.G. de Vries, A.G. van der Zee, and G.H. de Bock Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis Br J Cancer 101 2009 149 159
26. W. Xia, Y. Wei, Y. Du, J. Liu, B. Chang, Y.L. Yu, L.F. Huo, S. Miller, and M.C. Hung Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer Mol Carcinog 48 2009 610 617
27. S.B. Kaye, C.J. Poole, M. Bidzinksi, L. Gianni, V. Gorbunova, E. Novikova, A. Strauss, V.A. McNally, G. Ross, and I. Vergote A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer Proc Am Soc Clin Oncol 26 2008 5520 [abstr]
28. S. Makhija, L.C. Amler, D. Glenn, F.R. Ueland, M.A. Gold, D.S. Dizon, V. Paton, C.-Y. Lin, T. Januario, K. Ng, A. Strauss, S. Kelsey, M.X. Sliwkowski, and U. Matulonis Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer J Clin Oncol 2009 JCO.2009.22.3354
29. R.J. Schilder, M.W. Sill, X. Chen, K.M. Darcy, S.L. Decesare, G. Lewandowski, R.B. Lee, C.A. Arciero, H. Wu, and A.K. Godwin Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study Clin Cancer Res 11 2005 5539 5548
30. J.R. Wiener, T.C. Windham, V.C. Estrella, N.U. Parikh, P.F. Thall, M.T. Deavers, R.C. Bast, G.B. Mills, and G.E. Gallick Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers Gynecol Oncol 88 2003 73 79
31. A.H. Bild, G. Yao, J.T. Chang, Q. Wang, A. Potti, D. Chasse, M.B. Joshi, D. Harpole, J.M. Lancaster, A. Berchuck, J.A. Olson Jr., J.R. Marks, H.K. Dressman, M. West, and J.R. Nevins Oncogenic pathway signatures in human cancers as a guide to targeted therapies Nature 439 2006 353 357
32. Y. Pengetnze, M. Steed, K.F. Roby, P.F. Terranova, and C.C. Taylor Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line Biochem Biophys Res Commun 309 2003 377 383
33. T. Chen, Y. Pengetnze, and C.C. Taylor Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3 Mol Cancer Ther 4 2005 217 224
34. L.Y. Han, C.N. Landen, J.G. Trevino, J. Halder, Y.G. Lin, A.A. Kamat, T.J. Kim, W.M. Merritt, R.L. Coleman, D.M. Gershenson, W.C. Shakespeare, Y. Wang, R. Sundaramoorth, C.A. Metcalf III, D.C. Dalgarno, T.K. Sawyer, G.E. Gallick, and A.K. Sood Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma Cancer Res 66 2006 8633 8639
35. J.H. Hoeijmakers Genome maintenance mechanisms for preventing cancer Nature 411 2001 366 374
36. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, M. Santarosa, K.J. Dillon, I. Hickson, C. Knights, N.M. Martin, S.P. Jackson, G.C. Smith, and A. Ashworth Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
37. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M.J. O'Connor, A. Ashworth, J. Carmichael, S.B. Kaye, J.H. Schellens, and J.S. de Bono Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
38. M.W. Audeh, R.T. Penson, M. Friedlander, B. Powell, K.M. Bell-McGuinn, C. Scott, J.N. Weitzel, J. Carmichael, and A. Tutt Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer Proc Am Soc Clin Oncol 27 2009 5500 [abstr]
39. J.I. Weberpals, K.V. Clark-Knowles, and B.C. Vanderhyden Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway J Clin Oncol 26 2008 3259 3267
40. N. Turner, A. Tutt, and A. Ashworth Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 2004 814 819
41. R.L. Baldwin, E. Nemeth, H. Tran, H. Shvartsman, I. Cass, S. Narod, and B.Y. Karlan BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study Cancer Res 60 2000 5329 5333
42. N. Turner, A. Tutt, and A. Ashworth Targeting the DNA repair defect of BRCA tumours Curr Opin Pharmacol 5 2005 388 393
43. N. McCabe, N.C. Turner, C.J. Lord, K. Kluzek, A. Bialkowska, S. Swift, S. Giavara, M.J. O'Connor, A.N. Tutt, M.Z. Zdzienicka, G.C. Smith, and A. Ashworth Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 2006 8109 8115
44. K.R. Kalli, A.L. Oberg, G.L. Keeney, T.J. Christianson, P.S. Low, K.L. Knutson, and L.C. Hartmann Folate receptor alpha as a tumor target in epithelial ovarian cancer Gynecol Oncol 108 2008 619 626
45. G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli, and M. Boiocchi Overexpression of folate binding protein in ovarian cancers Int J Cancer 74 1997 193 198
46. W. Ebel, E.L. Routhier, B. Foley, S. Jacob, J.M. McDonough, R.K. Patel, H.A. Turchin, Q. Chao, J.B. Kline, L.J. Old, M.D. Phillips, N.C. Nicolaides, P.M. Sass, and L. Grasso Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha Cancer Immun 7 2007 6
47. D.K. Armstrong, A. Bicher, R.L. Coleman, D.G. Gibbon, D. Glenn, L. Old, N.N. Senzer, A. Schneeweiss, R.H. Verheijen, A.J. White, and S. Weil Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse Proc Am Soc Clin Oncol 26 2008 5500 [abstr]
48. R. Baserga The insulin-like growth factor-I receptor as a target for cancer therapy Expert Opin Ther Targets 9 2005 753 768
49. P.J. Beltran, P. Mitchell, G. Moody, J. Lu, Y. Chung, X. Zhang, D. Freeman, R.L. Kendall, F.J. Calzone, and R. Radisnky AMG-479, a fully human anti IGF-1 receptor antibody, inhibits PI3K/Akt signaling and exerts potent antitumor effects in combination with EGF-R inhibitors in pancreatic xenograft models Proc Am Soc Clin Oncol 207 2007 [abstr]
50. R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, J. Fowler, B.J. Monk, B.E. Greer, M. Boente, and S.X. Liang Phase III trial of bevcizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study J Clin Oncol 28 2010 part II 946s [abstr]
51. N. Wolmark, G. Yothers, M.J. O'Connell, S. Sharif, J.N. Atkins, T.E. Seay, L. Feherenbacher, S. O'Reilly, and C.J. Allegra A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 Proc Am Soc Clin Oncol 27 2009 LBA4 [abstr]